Mirati Therapeutics Gestion

Gestion contrôle des critères 3/4

Le PDG Mirati Therapeutics est Chuck Baum, nommé en Nov2012, a un mandat de 11.17 ans. La rémunération annuelle totale est $ 7.42M, composée du salaire de 9.2% et des bonus 90.8%, y compris les actions et options de la société. détient directement 0.16% des actions de la société, d'une valeur de € 6.05M. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 2.5 ans et 5.1 ans.

Informations clés

Chuck Baum

Directeur général

US$7.4m

Rémunération totale

Pourcentage du salaire du PDG	9.2%
Durée du mandat du directeur général	11.2yrs
Propriété du PDG	0.2%
Durée moyenne d'occupation des postes de direction	2.5yrs
Durée moyenne du mandat des membres du conseil d'administration	5.1yrs

Mises à jour récentes de la gestion

Recent updates

Analyse de la rémunération des PDG

Comment la rémunération de Chuck Baum a-t-elle évolué par rapport aux bénéfices de Mirati Therapeutics?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Sep 30 2023	n/a	n/a	-US$726m
Jun 30 2023	n/a	n/a	-US$738m
Mar 31 2023	n/a	n/a	-US$737m
Dec 31 2022	US$7m	US$685k	-US$741m
Sep 30 2022	n/a	n/a	-US$738m
Jun 30 2022	n/a	n/a	-US$645m
Mar 31 2022	n/a	n/a	-US$634m
Dec 31 2021	US$18m	US$662k	-US$582m
Sep 30 2021	n/a	n/a	-US$483m
Jun 30 2021	n/a	n/a	-US$491m
Mar 31 2021	n/a	n/a	-US$407m
Dec 31 2020	US$12m	US$615k	-US$358m
Sep 30 2020	n/a	n/a	-US$329m
Jun 30 2020	n/a	n/a	-US$296m
Mar 31 2020	n/a	n/a	-US$259m
Dec 31 2019	US$8m	US$597k	-US$213m
Sep 30 2019	n/a	n/a	-US$169m
Jun 30 2019	n/a	n/a	-US$142m
Mar 31 2019	n/a	n/a	-US$125m
Dec 31 2018	US$5m	US$580k	-US$98m
Sep 30 2018	n/a	n/a	-US$88m
Jun 30 2018	n/a	n/a	-US$77m
Mar 31 2018	n/a	n/a	-US$67m
Dec 31 2017	US$2m	US$563k	-US$70m

Rémunération vs marché: La rémunération totale de Chuck ($USD 7.42M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché German ($USD 1.90M ).

Rémunération et revenus: La rémunération de Chuck a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.

PDG

Chuck Baum (65 yo)

11.2yrs

Titularisation

US$7,420,213

Compensation

Dr. Charles M. Baum, M.D., Ph D., also known as Chuck, is a Director of Acrivon Therapeutics, Inc. from June 2023. Dr. Baum is an Independent Director of Poseida Therapeutics, Inc. from May 16, 2022.He se...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Charles Baum	Founder	11.2yrs	US$7.42m	0.16% € 6.0m
James Christensen	Executive VP & Chief Scientific Officer	10yrs	US$5.01m	0.082% € 3.1m
Alan Bart Sandler	Executive VP & Chief Medical Officer	1.2yrs	US$5.30m	0.014% € 540.4k
Aaron Ondrey	Chief Financial Officer	less than a year	pas de données	0.056% € 2.1m
Betsy Gelfand	Chief Accounting Officer	less than a year	pas de données	pas de données
John Moriarty	Chief Legal Officer & Corporate Secretary	less than a year	pas de données	pas de données
Peter Lee	Chief Compliance Officer	2yrs	pas de données	pas de données
Michael Paolucci	Chief People Officer	2yrs	pas de données	pas de données
Benjamin Hickey	Chief Commercial Officer	4yrs	US$6.93m	0.040% € 1.5m
Kelly Covello	VP & Head of Medical Affairs	3.8yrs	pas de données	pas de données
Ryan Asay	VP & Head of Corporate Affairs	3.8yrs	pas de données	pas de données
Susan Welsh	Senior VP of Pharmacovigilance & Chief Safety Officer	3yrs	pas de données	pas de données

2.5yrs

Durée moyenne de l'emploi

55yo

Âge moyen

Gestion expérimentée: L'équipe de direction de 26M est considérée comme expérimentée (ancienneté moyenne 2.5 ans).

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Charles Baum	Founder	11.2yrs	US$7.42m	0.16% € 6.0m
Bruce Leonard Carter	Independent Director	7.3yrs	US$700.41k	0.0086% € 325.2k
George Demetri	Member of Scientific Advisory Board	no data	pas de données	pas de données
Faheem Hasnain	Chairman & Lead Independent Director	4.9yrs	US$979.79k	0.012% € 471.1k
Julie Michele Cherrington	Independent Director	4.6yrs	US$697.91k	0% € 0
Stephen Baylin	Member of Scientific Advisory Board	no data	pas de données	pas de données
Lillian Siu	Member of Scientific Advisory Board	no data	pas de données	pas de données
Aaron Davis	Independent Director	5.1yrs	US$677.91k	0.061% € 2.3m
Pasi Antero Janne	Member of Scientific Advisory Board	5yrs	pas de données	pas de données
Craig Johnson	Independent Director	10.3yrs	US$702.91k	0.0086% € 325.2k
Channing Der	Member of Scientific Advisory Board	5yrs	pas de données	pas de données
Maria Martinez-Davis	Independent Director	5.1yrs	US$695.41k	0.0086% € 325.2k

5.1yrs

Durée moyenne de l'emploi

65yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de 26M sont considérés comme expérimentés (ancienneté moyenne 5.1 ans).

Mirati Therapeutics Gestion

Gestion contrôle des critères 3/4

Informations clés

Mises à jour récentes de la gestion

Mirati Therapeutics, Inc. Announces CFO Changes Effective as of September 8, 2023

Insufficient new directors

Mirati Therapeutics Appoints Carol Gallagher, Pharm.D. as New Independent Director

Chief Financial Officer recently sold €161k worth of stock

Insufficient new directors

CEO & Director recently sold €125k worth of stock

Recent updates

Mirati Therapeutics, Inc. Files Form 15

Mirati Therapeutics, Inc.(NasdaqGS:MRTX) dropped from NASDAQ Biotechnology Index

Bristol-Myers Squibb Company (NYSE:BMY) completed the acquisition of Mirati Therapeutics, Inc. (NasdaqGS:MRTX) from a group of shareholders.

Mirati Therapeutics, Inc. Receives Positive Opinion from CHMP for KRAZATI as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer with a KRASG12C Mutation Following a Re-Examination Procedure

Third quarter 2023 earnings released: US$2.49 loss per share (vs US$3.09 loss in 3Q 2022)

Mirati Therapeutics, Inc. Presents Late-Breaking Results Evaluating the Combination of Adagrasib and Pembrolizumab in First-Line Non-Small Cell Lung Cancer

Bristol-Myers Squibb Company (NYSE:BMY) entered into a definitive agreement to acquire Mirati Therapeutics, Inc. (NasdaqGS:MRTX) for $3.4 billion.

Bristol-Myers Squibb Company (NYSE:BMY) entered into a definitive agreement to acquire Mirati Therapeutics, Inc. (NasdaqGS:MRTX) for $3.4 billion.

Sanofi Reportedly Explores Potential Acquisition of Mirati Therapeutics

Mirati Therapeutics, Inc. Announces CFO Changes Effective as of September 8, 2023

Mirati Therapeutics, Inc. Publishes Preclinical and Initial Clinical Data for MRTX1719 to Treat MTAP-Deleted Cancers Through Novel Approach to MTA-Cooperative PRMT5 Inhibition

Insufficient new directors

Second quarter 2023 earnings released: US$3.04 loss per share (vs US$3.18 loss in 2Q 2022)

New minor risk - Insider selling

Mirati Therapeutics, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Mirati Therapeutics Provides Update on Regulatory Review in the European Union of Krazati (Adagrasib) for the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) with A Krasg12c Mutation

Mirati Therapeutics Appoints Carol Gallagher, Pharm.D. as New Independent Director

Chief Financial Officer recently sold €161k worth of stock

Mirati Therapeutics Provides Update on the Phase 3 SAPPHIRE Study Evaluating Sitravatinib in Combination with OPDIVO(R)

Insufficient new directors

Mirati Therapeutics, Inc. to Report Q4, 2022 Results on Feb 28, 2023

CEO & Director recently sold €125k worth of stock

Mirati Therapeutics, Inc. Announces U.S. Food and Drug Administration Clears the Investigational New Drug (Ind) Application of MRTX1133

Founder recently sold €160k worth of stock

Executive VP & Chief Scientific Officer recently sold €98k worth of stock

Mirati announces Adagrasib (KRAZATI™) Receives Breakthrough Therapy Designation from FDA for Patients with Advanced, KRAS-Mutated Colorectal Cancer and NEJM Publishes Phase 1b/2 Data from Adagrasib With or Without Cetuximab in Colorectal Cancer

Mirati Therapeutics, Inc. Announces U.S. FDA Accelerated Approval of KRAZATI™ (adagrasib) as a Targeted Treatment Option for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation

Executive VP & Chief Scientific Officer recently sold €148k worth of stock

Mirati Therapeutics Presents Late-Breaking Results Evaluating Concurrent Adagrasib and Pembrolizumab in First-Line Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

Mirati Therapeutics, Inc. Announces Update for the Phase 3 SAPPHIRE Study

Mirati Therapeutics Reportedly Seen as Takeover Target Once Again

Mirati Therapeutics, Inc. Announces Management Changes

Mirati Therapeutics, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Mirati Therapeutics, Inc. Presents Late-Breaking Adagrasib Monotherapy and Combination

Mirati Therapeutics, Inc. to Report Q2, 2022 Results on Aug 03, 2022

Mirati Therapeutics, Inc. Announces Results of A Prospective Analysis from the Phase 1B Cohort of the KRYSTAL-1

Mirati Therapeutics Announces Investigational Adagrasib Delivers Positive Results in Registration-Enabling Study of Patients with KRASG12C-Mutated Advanced Non-Small Cell Lung Cancer

Mirati Therapeutics, Inc. Submits Marketing Authorization Application to the European Medicines Agency for Investigational adagrasib as a Treatment

Mirati Therapeutics Appoints Laurie Stelzer as Chief Financial Officer

Mirati Therapeutics, Inc. to Present New Research at the 2022 ASCO Annual Meeting Showcasing Clinical Advances of Treating KRASG12C-Mutated Lung Cancer with Investigational Adagrasib

Mirati Therapeutics, Inc. to Report Q1, 2022 Results on May 04, 2022

Mirati Therapeutics, Inc., Annual General Meeting, May 12, 2022

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

U.S. Food and Drug Administration Accepts New Drug Application for Adagrasib as Treatment of Previously Treated Krasg12c-Mutated Non-Small Cell Lung Cancer

Mirati Therapeutics, Inc. to Report Q4, 2021 Results on Feb 28, 2022

Mirati Therapeutics, Inc. Presents Positive Clinical Data with Investigational Adagrasib in Patients with KRASG12C -Mutated Gastrointestinal Cancers

Chief Commercial Officer recently sold €67k worth of stock

Chief Commercial Officer recently sold €235k worth of stock

Chief Scientific Officer recently sold €139k worth of stock

High number of new directors

High number of new directors

Independent Director Michael Grey has left the company

Mirati Therapeutics, Inc.(NasdaqGS:MRTX) dropped from Russell 2000 Growth Index

Mirati Therapeutics' Adagrasib Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for Patients with Advanced Non-Small Cell Lung Cancer Harboring the KRAS G12C Mutation

Chief Scientific Officer recently sold €55k worth of stock

Mirati Therapeutics to Present Late-Breaking Data That Advance the Understanding of Synthetic Lethal PRMT5 Inhibitors in MTAP-Deleted Cancers at AACR 2021

Analyse de la rémunération des PDG

PDG

Titularisation

Compensation

Équipe de direction

Durée moyenne de l'emploi

Âge moyen

Membres du conseil d'administration

Durée moyenne de l'emploi

Âge moyen